Finance

Lists
BIIB34:BVMF
Biogen Inc BDR
၂၃၀.၁၀ R$
၀.၀၀%
(၀.၀၀) 1D
နို ၄, GMT-၃ ၁၅:၃၈:၀၇  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB34...
Mkt. cap
ဋေ ၃.၇၅ ထ
Avg. vol.
၉.၀၀
Volume
၀.၀၀
52-wk high
၂၃၀.၁၀ R$
52-wk low
၁၄၅.၆၅ R$
Shares outstanding
၁၄.၇၈ ကုဋေ
No. of employees
၈ ထောင်
Mkt. cap
ဋေ ၃.၇၅ ထ
Avg. vol.
၉.၀၀
Volume
၀.၀၀
52-wk high
၂၃၀.၁၀ R$
52-wk low
၁၄၅.၆၅ R$
Shares outstanding
၁၄.၇၈ ကုဋေ
No. of employees
၈ ထောင်
News stories
From web sources and news partners
Stocks Down Under
Stocks Down Under
·
ပြီးခဲ့သည့် ၂၂ နာရီ
Biogen (NYSE:BIIB) Share Price, Forecast & Analysis
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees၇.၅ ထောင်
Founded၁၉၇၈
Headquartersကင်းဘရစ်ချ်, မက်ဆာချူးဆက်ပြည်နယ်, ယူနိုက်တက်စတိတ်
SectorHealth Care
Industry-
Websitebiogen.com
Last report
၂၀၂၆ အောက် ၂၈
Fiscal period
Q3 2026
၂.၆၂ US$ / ၁.၉၉ US$
+၃၁.၅၃%beat
Revenue / Est. (USD)
၂၈၀.၄၁ ဋေ / ၂၆၃.၁၄ ဋေ
+၆.၅၆%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
၂၀၂၆ စက်
Revenue
၂၂၇.၉၄ ဋေ
၂၄၇.၇၈ ဋေ
၂၇၃.၆၀ ဋေ
၂၈၀.၄၁ ဋေ
Cost of goods sold
၄၄.၃၄ ကုဋေ
၁၀၉.၂၄ ဋေ
၁၁၀.၃၇ ဋေ
၁၁၂.၅၂ ဋေ
Cost of revenue
၄၄.၃၄ ကုဋေ
၁၀၉.၂၄ ဋေ
၁၁၀.၃၇ ဋေ
၁၁၂.၅၂ ဋေ
Research and development expenses
၄၇.၇၁ ကုဋေ
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၆၈.၅၂ ကုဋေ
၆၀.၇၃ ကုဋေ
၇၀.၉၇ ကုဋေ
၇၅.၂၀ ကုဋေ
Operating expense
၁၃၆.၄၄ ဋေ
၈၁.၈၀ ကုဋေ
၉၄.၆၇ ကုဋေ
၁၀၀.၂၆ ဋေ
Total operating expenses
၁၈၀.၇၈ ဋေ
၁၉၁.၀၄ ဋေ
၂၀၅.၀၄ ဋေ
၂၁၂.၇၈ ဋေ
Operating income
၄၇.၁၆ ကုဋေ
၅၆.၇၄ ကုဋေ
၆၈.၅၆ ကုဋေ
၆၇.၆၃ ကုဋေ
Other non operating income
၁.၇၄ ကုဋေ
-၁.၁၀ သန်း
၃.၀၀ သန်း
၁.၁၂ ကုဋေ
EBT including unusual items
-၅.၆၀ ကုဋေ
၃၇.၇၇ ကုဋေ
၁၃.၂၄ ကုဋေ
-၉.၀၀ သန်း
EBT excluding unusual items
၄၄.၇၀ ကုဋေ
၅၃.၀၁ ကုဋေ
၆၂.၅၁ ကုဋေ
၆၀.၃၀ ကုဋေ
Income tax expense
-၇.၁၀ သန်း
၅.၈၂ ကုဋေ
၃.၄၉ ကုဋေ
၁.၁၆ ကုဋေ
Effective tax rate
၁၂.၆၈%
၁၅.၄၁%
၂၆.၃၆%
-၁၂၈.၈၉%
Other operating expenses
၆.၉၉ ကုဋေ
၇.၄၂ ကုဋေ
၆.၈၈ ကုဋေ
၇.၇၈ ကုဋေ
Net income
-၄.၈၉ ကုဋေ
၃၁.၉၅ ကုဋေ
၉.၇၅ ကုဋေ
-၂.၀၆ ကုဋေ
Net profit margin
-၂.၁၅%
၁၂.၈၉%
၃.၅၆%
-၀.၇၃%
Earnings per share
၁.၉၉
၃.၅၇
၃.၆၀
၂.၆၂
Interest and investment income
၃.၇၂ ကုဋေ
၃.၇၉ ကုဋေ
၂.၅၃ ကုဋေ
၉.၃၀ သန်း
Interest expense
-၆.၇၅ ကုဋေ
-၆.၇၆ ကုဋေ
-၈.၂၃ ကုဋေ
-၈.၇၅ ကုဋေ
Net interest expenses
-၃.၀၃ ကုဋေ
-၂.၉၇ ကုဋေ
-၅.၇၀ ကုဋေ
-၇.၈၂ ကုဋေ
Depreciation and amortization charges
-
-
-
-
EBITDA
၆၇.၁၈ ကုဋေ
၇၇.၁၈ ကုဋေ
၉၂.၁၇ ကုဋေ
၉၁.၇၄ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google အက်ပ်များ